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CD30, a member of the TNF receptor superfamily, is selectively expressed on a
subset of activated lymphocytes and on malignant cells of certain lymphomas, such
as classical Hodgkin Lymphoma (cHL), where it activates critical bystander cells in the
tumor microenvironment. Therefore, it is not surprising that the CD30 antibody-drug
conjugate Brentuximab Vedotin (BV) represents a powerful, FDA-approved treatment
option for CD30+ hematological malignancies. However, BV also exerts a strong anti-
cancer efficacy in many cases of diffuse large B cell lymphoma (DLBCL) with poor
CD30 expression, even when lacking detectable CD30+ tumor cells. The mechanism
remains enigmatic. Because CD30 is released on extracellular vesicles (EVs) from both,
malignant and activated lymphocytes, we studied whether EV-associated CD30 might
end up in CD30− tumor cells to provide binding sites for BV. Notably, CD30+ EVs bind
to various DLBCL cell lines as well as to the FITC-labeled variant of the antibody-drug
conjugate BV, thus potentially conferring the BV binding also to CD30− cells. Confocal
microscopy and imaging cytometry studies revealed that BV binding and uptake depend
on CD30+ EVs. Since BV is only toxic toward CD30− DLBCL cells when CD30+ EVs
support its uptake, we conclude that EVs not only communicate within the tumor
microenvironment but also influence cancer treatment. Ultimately, the CD30-based BV
not only targets CD30+ tumor cell but also CD30− DLBCL cells in the presence of
CD30+ EVs. Our study thus provides a feasible explanation for the clinical impact of BV
in CD30− DLBCL and warrants confirming studies in animal models.
Keywords: tumor microenvironment, cellular crosstalk, immune therapy, antibody-drug conjugate, extracellular
vesicle
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INTRODUCTION
CD30 is a transmembrane protein of the TNF receptor
superfamily (TNFRSF8). It is restricted to a small population
of activated T and B immunoblasts in lymphoid tissue of
healthy individuals (Stein et al., 1985; Horie and Watanabe,
1998). In T cells, CD30 serves as a costimulatory receptor,
which is upregulated by T cell receptor (TCR) and CD28
ligation in addition to the action of cytokines, such as IL-
4 (Gilfillan et al., 1998). Normal CD30+ B cells are mostly
class-switched and express CD27 (TNFRSF7) (Weniger et al.,
2018). The corresponding ligand (CD30L/TNFSF8) is also a
transmembrane protein, which is weakly expressed on various
immune cells including neutrophils, eosinophils, lymphocytes,
myeloid cells, and mast cells. Here, the binding of membrane-
associated CD30 causes reverse signaling and context-dependent
pleiotropic effects, ranging from degranulation-free activation
of myeloid cells to B cell inhibition (Wiley et al., 1996;
Cerutti et al., 2000). In mice, constitutively active CD30 in
B cells is associated with augmented B1-B and plasma cell
counts, implicating NF-κB signaling and STAT 3 and STAT6
phosphorylation (Sperling et al., 2019). When aged, such
mice have an enhanced risk of lymphomagenesis. Additionally,
CD30 is expressed in transformed cells of certain malignant
lymphomas, such as classical Hodgkin Lymphoma (cHL) and
systemic Anaplastic Large Cell Lymphoma (sALCL; Horie and
Watanabe, 1998). Because of its selective expression in malignant
cells, CD30 became of interest for targeted immunotherapy
with the monomethyl auristatin E (MMAE)-coupled humanized
CD30 antibody drug conjugate (ADC) Brentuximab Vedotin
(BV; Wahl et al., 2002). After internalization of the ADC, the
acidic milieu of the lysosomes releases MMAE that is able
to inhibit microtubule formation (Sutherland et al., 2006). In
a pivotal study, BV treatment of sALCL and cHL patients,
who relapsed after standard therapy, resulted in an overall
response rate of 86 and 75%, respectively (Younes et al., 2012).
Interestingly, BV proved also effective against other malignancies
with less pronounced CD30 expression.
Recent clinical studies revealed that a minor percentage of
diffuse large B cell lymphoma (DLBCL) patients had tumor
cells with CD30 expression (Hu et al., 2013). Visually assessed
immunohistochemistry (IHC) identified CD30+ tumor cells in
about 25% of DLBCL cases (Slack et al., 2014). However, unbiased
computer-assisted IHC, which calculates also non-malignant
CD30+ cells, identified higher case numbers (36%) (Bartlett et al.,
2017). Remarkably, clinical trials with BV in DLBCL patients
suggested that the response to BV-treatment did not correlate
with the amount of CD30+ tumor cells. In one case, a complete
remission was achieved with BV even when CD30+ tumor cells
were not detectable (Jacobsen et al., 2015). These data suggest that
the CD30 transfer from non-malignant cells might contribute to
the clinical efficacy of BV.
Extracellular vesicles (EVs) are released by virtually all cell
types. They originate from the outward budding of multivesicular
endosomes or budding from the plasma membrane. Endosome-
derived EVs are referred to as small EVs (s-EVs, exosomes)
and are generally smaller than plasma membrane-derived
large EVs (l-EVs or microvesicles) (Thery et al., 2009;
Nishimura et al., 2021). Both EV types are membrane-
enclosed particles and harbor typical traits of the donor cells,
including nucleic acids, lipids, and soluble and membrane-
associated proteins. By binding to or fusing with cells in the
proximity or at distant sites, EVs are able to communicate
in trans in a cell contact-like manner with recipient cells
and thus undoubtedly represent an important intercellular
communication tool (Tkach and Thery, 2016).
In a previous study, we showed that EVs of cHL cells, carry
CD30 as a cargo and bind to and are taken up by typical bystander
cells (Hansen et al., 2016). In the presence of BV, the CD30+
EVs are able to mediate cell damage also to CD30− cells in a
CD30+ EV-dependent manner. Thus, the transport of CD30 to
bystander cells enables a dual targeting of CD30+ tumor and
CD30− supporter cells. Since DLBCL presents as a heterogeneous
disease, encompassing cases with variable CD30+ tumor and/or
CD30+ bystander cells, a functional EV-dependent transport
from CD30+ cells to CD30− DLBCL cells might explain the
efficacy of BV in cases with CD30− tumor cells. In our study, we
provide strong evidence, that CD30+ EVs are able to bind and
transport BV functionally to CD30+ or CD30− DLBCL cells.
MATERIALS AND METHODS
Cells and Reagents
The cell lines L540, THP-1, P30/OHKUBO and DoHH-2 were
purchased from the DSMZ (Braunschweig, Germany). Karpas
422 was from Sigma Aldrich (St. Louis, MO, United States). Cells
were cultivated at 37◦C and 5% CO2 in RPMI 1640 containing
10% FBS, supplemented with GlutaMAX, 100 U/mL penicillin
and 100 µg/mL streptomycin. The following additional reagents
were used: PE Annexin V (RRID: AB_2561298), PE anti-human
CD30 (RRID: AB:2207595), PE goat anti mouse IgG (RRID:
AB_315010), anti-human CD81 (RRID: AB_10643417), anti-
human CD9 (RRID: AB_314907), anti-human CD63 (RRID:
AB_11204263), anti-human CD54 (RRID: AB_535974). The
SGN30 antibody was from Seattle Genetics (Bothell, WA,
United States). In fluorescence studies, the antibody was coupled
with FITC (Sigma) in a 0.2 M carbonate buffer at pH 9.2 and
purified by subsequent gel filtration. The CD30 antibody Ki-
3 (Horn-Lohrens et al., 1995) was labeled with the deep red
fluorescence dye CF 594 (Sigma) according to the manufacturer’s
instruction. The sheddase inhibitor Ro 32-7315 was kindly
provided by Roche Diagnostics, Penzberg, Germany. The anti-
CD30 hybridoma HeFi-1 was kindly provided by Dr. Ellis, Loyola
Univ., Maywood, IL, United States.
Vesicle Isolation
Cells were cultivated under serum-free conditions at 5× 106/mL
for 2 h in the presence of 10 µM Ro 32-7315. Cell supernatant was
collected and cleared by three consecutive centrifugation steps,
i.e., 5 min at 300 × g, 10 min at 1,000 × g, 20 min at 3,500 × g.
Cleared supernatants were sedimented in an ultracentrifuge for
2 h at 100,000 × g. Vesicle-containing pellets were washed twice
with PBS by ultracentrifugation. Particle concentration and size
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distribution of isolated EVs were determined by nanoparticle
tracking analysis (NTA, Nanosight NS300, Malvern Instruments).
The means of five consecutive measurements of 1 min were
evaluated to adjust the EV concentration to 1× 1010 EVs/mL.
Flow Cytometry of EVs
Extracellular vesicles were incubated at 4◦C overnight with
4.5 µm Polybead carboxylate microspheres (Polysciences,
Warrington, PA, United States). The beads were blocked
with 1% BSA (v/w) in PBS for 1h at 800 rpm. Then,
aliquots were incubated with fluorescence-labeled antibodies.
Beads were evaluated by flow cytometry on a Gallios device
(Beckman Coulter).
Electron Microscopy
Extracellular vesicles were fixed with 2% formaldehyde (Merck).
A 100 mesh formvar coated copper grid (Science Services) was
placed onto 5 µL of sample and incubated for 20 min. Grids were
washed seven times for 2 min in PBS and place for 5 min on
a drop of 1% glutaraldehyde (Merck). Grids were washed eight
times in ddH2O. Grids were placed for 4 min onto a drop of 1.5%
aqueous uranyl acetate and blotted with a filter paper. Images
were acquired using a JEM-2100 Plus Transmission Electron
Microscope (JEOL) operating at 80kV equipped with a OneView
4K camera (Gatan).
EV-Labeling With DiD
Extracellular vesicles were isolated and washed with PBS by
ultracentrifugation at 100,000 × g and subsequently labeled with
40 nM of the membrane dye DiD (1,1′-Dioctadecyl-3,3,3′,3′-
tetramethylindo-dicarbo-cyanine, 4-Chlorobenzenesulfonate
salt, Thermo Fisher Scientific). Then, EVs were incubated for
20 min at 37◦C and washed by ultracentrifugation at 100,000× g
for 1 h at 4◦C. Afterward DiD-labeled EVs were added to the
target cell lines, incubated for 2 h at 4◦C and cells were then
analyzed by flow cytometry.
LC-MS/MS
The peptide mixture was analyzed in an LTQ Orbitrap
Velos (Thermo Fisher Scientific) mass spectrometer coupled
to nanoflow liquid chromatography on an EASY-nLC system
(Proxeon Biosystems) with a Proxeon nanoelectrospray ion
source. The parameters for MS analysis are described in further
detail in Supplementary Figure 1. The mass spectrometry
proteomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE partner repository with the dataset
identifier PXD025442 (Perez-Riverol et al., 2019).
Confocal Laser-Scanning Microscopy
Eight-well µ-slides (Ibidi) were coated over night with
0.01% poly-L-lysine at 37◦C and afterwards washed three
times with medium. Cells were let to adhere and incubated
with Ki-3-CF594-loaded EVs for 1 h. Then, the medium
was carefully removed and replaced with fresh medium,
containing CellMaskTM Deep Red Plasma membrane stain
(649/666 nm; Thermo Fisher Scientific) and Hoechst 33342
dye (NucBlueTM Live ReadyProbesTM, Thermo Fisher
Scientific). After 5 min incubation, the dye-containing
medium was substituted by fresh medium and the samples
immediately subjected to the confocal laser scanning
microscope (Leica TCS SP8, 63x PlanApo oil objective
N.A. 1.4) with super resolution (∼50 nm lateral, 120 nm
axial).
Measurement of EV Uptake by Imaging
Flow Cytometry (ImageStream)
Target cells (5× 105) were washed twice with FACS buffer before
incubation with SGN30-FITC ± EVs for 1 h at RT to allow
EV binding and internalization. Then, cells were washed once
with cold FACS-buffer and then fixed with 1% PFA in PBS and
subsequently kept on ice until internalization could be analyzed
by imaging flow cytometry.
Internalization of FITC-labeled SGN30 antibody and CD30+
EVs by Karpas 422 or P30-OH/KUBO cells was quantified
by imaging flow cytometry using an ImageStream X Mark
II one camera system with 351, 488, 562, 658 and 732 nm
lasers (Merck Millipore, Burlington, MA, United States). The
system was calibrated using SpeedBeads (Merck Millipore) prior
to use and at least 10,000 events with an area >12.5 µm2
based on bright field images were acquired. Moreover, 500–
1,000 events of single stained compensation control samples
gated on appropriate signal size were acquired with both
the bright field channel and the 732 nm laser turned off.
Images (bright field in channel 1 and FITC in channel 2
(505–560 nm) were acquired at 60-fold magnification. The
integrated software INSPIRE R© was used for data collection as
raw image files. Single color controls were used to calculate
a spectral crosstalk matrix that was applied to each raw
image file for spectral compensations in the detection channels.
The analysis was performed on the compensated image files
using the IDEAS R© image analysis software. The bright field
gradient root mean square (RMS) feature was used to gate
on focused cells and dot plots of the bright field area versus
the aspect ratio were used to gate on single cells. The
internalization wizard was used to calculate the internalization
score that is defined as the ratio of the intensity inside
the cell to the intensity of the entire cell mapped to a
logarithmic scale.
Toxicity Test
Target cells (1 × 105 cells/well) were cultivated in 500 µL
medium/well in a 24-well plate ± 109 EVs from L540 or
THP-1 along with different amounts of BV ± HeFi-1 antibody
(1 µg/mL final concentration) or medium alone as control.
After 24 h another 250 µL of culture medium was added
to each well. The cells were further incubated for 48 h and
cell viability was assessed by flow cytometry. To this end,
the cells were washed once with FACS buffer, then stained
with propidium iodide (PI; 0.5 µg/mL) for 30 min at 4◦C,
washed twice with FACS buffer and PI+ cells were determined
by flow cytometry.
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Statistical Analysis
If not stated otherwise, all experiments were performed in
at least three independent replicates. Results obtained from
representative experiments are shown. Data (n≥ 3) are presented
as mean± standard errors of the mean (SEM) and were analyzed
using GraphPad Prism 7 software. Statistical significance was
calculated as indicated in the Figures.
RESULTS
Production of CD30+ EVs
In many cases of DLBCL, cells with variable expression of
CD30 are admixed in the affected tissue. They are either
malignant themselves or reactive immunoblasts (Figure 1A).
Here, we studied whether EVs from CD30+ cells contribute
to the efficacy of BV in DLBCL. In order to generate CD30+
EVs for subsequent experiments, we cultivated the CD30+ L540
cell line for 1 h under serum-free conditions and harvested the
cell supernatant. The l-EVs sediment at lower gravity than the
s-EVs (Nishimura et al., 2021). In order to determine, which
EV type preferentially contains CD30, we compared EVs that
sediment at different gravity. After two centrifugation steps at
low gravity to remove cell debris, we collected vesicles that
sediment at 10,000 × g and another portion from a subsequent
ultracentrifugation step at 100,000× g (Figure 1B). Nanoparticle
tracking analysis (NTA) revealed that the 10,000 × g fraction
contained roughly 4× less but larger vesicles than the 100,000× g
fraction, i.e., 6.97 × 108 ± 3.94 × 107 particles/mL with a
mean diameter of 205 nm and 3.24 × 109 ± 1.03 × 108
with a mean diameter of 143 nm, respectively. Because both
particle fractions are deliberately released into the environment,
they are candidate vehicles, provided they contain CD30. Mass
spectrometry demonstrated that both EV fractions yielded a
similar amount of protein hits with largely overlapping genes,
including CD30, i.e., 81% of the 10,000 × g and 83% of the
100,000 × g fraction (Figure 1C and Supplementary Table 1).
Interestingly, both EV preparations contained almost exclusively
hits, which are found in the EV protein database Vesiclepedia,
i.e., 98.5 and 97.3% in the 10,000 × g and 100,000 × g fractions,
respectively (Supplementary Figure 1). Also, categorization
of the protein hits with the Funrich 3.1.4 software revealed
that similar percentages were allocated to different cellular
components, whereof the category of exosomes was the most
prominent one. Because of the similar protein composition,
particularly the presence of CD30, we pooled the 10,000 × g and
the 100,000 × g fraction for further experiments. EVs from the
CD30− cell line THP-1 were tested as a control. Transmission
electron microscopy of the pooled fractions identified in both
cases (OsO4-stained) membrane-enclosed particles of variable
diameter within the range of EVs. NTA measurement showed
a similar EV diameter in the pooled fractions from L540 and
the THP1 cell, i.e., 165.0 ± 67.5 nm (L540) and 172 ± 63.9 nm
(THP-1) (Figure 1D). As expected, EVs from both cell types
expressed typical EV markers such as phosphatidylserine and
tetraspanins (CD63, CD81, and CD82) but only EVs from L540
cells contained CD30 (Figure 1E). Therefore, we used L540
EVs as CD30 carriers and THP-1 EVs as negative controls in
subsequent experiments.
Targeting of Leukemia Cells With CD30+
EVs
To study the efficacy of CD30+ EVs in mediating BV toxicity
in non-Hodgkin B cell leukemia, we examined three target
cell lines for endogenous CD30 expression, binding of donor
cell EVs and enrichment of CD30 through EV binding. Flow
cytometry showed that the cell lines Karpas 422 and DoHH-2
(GC-DLBCL) had no detectable CD30, whereas P30-OH/KUBO
was positive for CD30 (Figure 2A, left). All tested cell lines
were able to bind or take up fluorescence-labeled EVs from
both L540 and THP-1 cells (Figure 2A, middle). As expected,
only the addition of EVs from L540 cells cumulated CD30 at
the cell surface of the CD30− cell lines (Figure 2A, right).
We determined the EV-dependent enrichment of CD30 in the
cells by flow cytometry, comparing the CD30-depending mean
fluorescence intensity between untreated and EV-treated cells.
The bars indicate, that among the tested cells, Karpas 422
showed better cell surface enrichment of EV-borne CD30 than
DoHH-2 after 2 h of incubation time. In P30-OH/KUBO with
endogenous CD30, EVs from L540 did not contribute much to
the overall cell surface expression of CD30. Our data showed
that universally membrane-labeled EVs generate a stronger signal
on target cells than the anti-CD30 staining. As shown in a
dot-plot, only a limited percentage of target cells accumulates
CD30+ EVs (median 0.52–6.55%, N = 11; Figure 2B). This
is not surprising because EVs from one source are generally
very heterogeneous in protein composition and only a certain
percentage might contain CD30 (Lee et al., 2018). In addition,
the internalization rate of CD30 might be different between
cell types upon ligation, and a variable amount of CD30 might
have been internalized following antibody binding. Because
CD30 antibody internalization is the aim in therapy, we studied
the internalization of anti-CD30 antibody. To approach this
question, we performed a series of imaging experiments, after
coincubation of target cells with EVs and fluorescent anti-CD30
antibody. Unfortunately, the antigen binding of BV dropped
after labeling with FITC, so for this set of experiments we
used either SGN30, which is the humanized backbone of BV
or the murine CD30 antibody Ki-3, which belongs to the same
serological cluster as SGN30/35 (Horn-Lohrens et al., 1995).
Confocal microscopy indicated that both CD30− Karpas 422 and
DoHH-2 have a clear CD30+ EV-dependent uptake of CD30
antibody (Figure 2C). CD30− EVs from THP1 cells did not
support this effect. Microscopy suggested a stronger signal inside
the cells than on the cell surface, partially explaining the low
EV-dependent surface CD30 in Figures 2A,B. Quantification of
the antibody uptake was approached by imaging flow cytometry
(Figure 2D). We determined the internalization score of SGN30-
FITC from cells incubated with L540-EVs, resulting in values
of 3.1 (N = 2156) for Karpas 422 cells and 2.1 (N = 1086) for
P30-OH/KUBO cells. These data indicate that both cell types
display uptake of the BV antibody backbone in the presence of
CD30+ EVs.
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FIGURE 1 | Characterization of CD30+ EVs. (A) Tissue section of lymph node infiltrated with DLBCL cells, which was stained with CD30 mAb (Ber-H2). The bar
indicates 100 µm. (B) Characterization of EVs from the cell supernatant of L540 cells. They were isolated by a series of centrifugation steps. The 10,000 × g and the
subsequent 100,000 × g fraction were studied by NTA and mass spectrometry. (C) The common and individual mass spectrum hits are shown in a Venn diagram.
(D) The pooled 10,000 × g and 100,000 × g EV fractions of L540 and THP-1 supernatants were studied by transmission electron microscopy. The diameter (x-axis)
and count (y-axis) of the EVs from the cell supernatant of L540 and THP-1 cells were analyzed by NTA. (E) The EVs were bound to 10 µm microspheres and
analyzed by flow cytometry. The EVs were stained for CD9, CD30, CD63, CD81, CD54, and phosphatidylserine (red) and compared to the isotype controls (gray).
We also determined the functionality of CD30+ EVs regarding
BV-induced cytotoxicity in CD30− Karpas 422 cells (Figure 3).
BV alone had no significant influence on the cell viability after
three days of incubation, resulting in 93.6, 93.4, and 92.2%
viability after treatment with 1, 3 and 10 µg/mL BV, respectively.
However, after the addition of CD30+ EVs (1× 109/mL), the cell
viability decreased significantly upon BV treatment, consequently
resulting in cell viability of 86.5, 84.9, and 66.2% respectively.
This effect was dependent on CD30 because the addition of the
competitive CD30 antibody HeFi-1 could neutralize the toxicity,
yielding improved cell viability of 90.3, 91.9, and 86.9%. The
antibody-dependent neutralization provides a strong argument
that the cytotoxicity of BV in such CD30− target cells is indeed
dependent on CD30+ EVs. We also tested the influence of
CD30+ EVs on the toxicity of BV in the CD30+ cell line
P30-OH/KUBO (Supplementary Figure 2). Although these cells
constitutively express CD30 and BV is able to directly target
them, this experiment provides initial evidence that CD30+ EVs
might contribute to or enhance the toxicity of BV even in CD30+
cells (Figure 4).
DISCUSSION
The functional efficacy of the CD30 ADC BV is well-established
in the treatment of lymphomas with high expression of CD30
in tumor cells (Younes et al., 2012). In DLBCL, the CD30
expression is variable, ranging from cases with a high percentage
to cases without detectable CD30 expression. Depending on
the sensitivity of the readout and whether bystander cells were
included in the calculation, the CD30+ cases range from 12
to 36% (Slack et al., 2014). However, DLBCL patients without
CD30+ tumor cells still profit from the BV therapy, in rare
cases even with complete remission. This observation raises the
question of the underlying mode of action in CD30− tumor cells.
Here, we studied a possible function of CD30+ EVs conveying the
anti-tumor functionality of BV. Major findings of our study are
that (i) the targeting antigen CD30 is present on l-EVs and s-EVs
from L540 cells, (ii) such EVs bind to both, the immunotoxin
BV and the DLBCL cells, (iii) EVs are taken up by target cells,
and (iv) dependent on BV and CD30+ EVs, such BV-loaded EVs
also damage CD30− DLBCL cells dependent on BV and CD30+
EVs (Figure 4).
In most cases, tumor cells do not grow independently
but require the support of other malignant cells and tumor-
(re)programmed non-malignant bystander cells. Therefore, in
addition to addressing the malignant cells quantitatively, the
targeting of the supporting tumor microenvironment has become
an emerging focus of modern cancer therapy. As an example,
the targeting of tumor-supporting CD25+ Treg cells with 90Y-
daclizumab (anti-CD25) significantly improves clinical responses
in cHL patients (Janik et al., 2015). This effect has also
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FIGURE 2 | Extracellular vesicle-dependent binding and incorporation of CD30 and BV. (A) The first column of graphs shows a flow cytometric analysis of the CD30
expression on the target cells Karpas 422, P30-OH/KUBO and DoHH-2 (red) compared to the isotype control (gray). The next two columns show the binding/uptake
of purified EVs from the supernatant of L540 or THP-1 cells (red). For that, the cells were treated for 2 h at 4◦C with DiD-labeled EVs. Untreated cells served as
controls (gray). To the right, the two columns show the amount of CD30 after binding of EVs from L540 or THP-1 cells (red) as compared to the isotype control
(gray). The adjacent bars indicate the relative increase of the CD30 mean fluorescence intensity (MFI) by the indicated EVs. (B) CD30 expression of Karpas 422
measured by flow cytometry, first gated on living cells and then the percentage of CD30+ cells was calculated with and without EVs; shown as a representative
image without EVs (upper left) and with EVs (upper right), and in a diagram summarizing the results of 11 measurements. (C) Confocal microscopy of Karpas 422
and DoHH-2 with L540 EVs (left panel) or THP-1 EVs (right). Cells were incubated with Ki-3-CF594-loaded EVs and the cell membrane was subsequently stained
with CellMask deep red. The fold change of CD30 expression after L540 and THP-1 EVs binding was measured by flow cytometry and normalized to the samples
without EVs. (D) The internalization process was further analyzed by one imaging flow cytometry investigation. The specific intensity of the green fluorescence is
depicted [(left), black]. Representative images are shown of Karpas 422 and P30-OH/KUBO cells, incubated with FITC-labeled SGN30 and EVs from L540 cells for
60 min at 37◦C. Scale bars represent 7 µm. Histograms displaying the internalization score are shown.
been explained by the collateral damage of the radio isotope,
targeting primarily tumor-rosetting T cells and also neighboring
tumor cells. Such a crossfire effect was also suggested for the
functionality of BV. After uptake of BV and cleavage of the toxic
MMAE in the target cells, it was suggested that a small amount of
MMAE passively penetrates the plasma membrane and diffuses
back into the cell environment where it damages neighboring
cells (Okeley et al., 2010).
In the last decade, the understanding of the role of EVs in
the intercellular communication has significantly improved. Such
EVs are also advancing cancer treatment and their influence on
the PD1/PD-L1 system might be regarded as a typical example. In
many malignant tumors, the immune surveillance fails because
the malignant cells express programmed cell death ligands such
as PD-L1, which, after cell contact, inhibit PD-1-expressing
immune surveillance cells. Recently, it was shown, that malignant
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FIGURE 3 | Viability assay of Karpas 422. Viability assay of Karpas 422 ± EVs from L540 cells with the addition of BV in different concentrations 1, 3, and 10 µg/mL
(from left to right); ± the inhibitory anti-CD30 antibody HeFi-1. The percentage of living cells was analyzed by flow cytometry using the propidium iodide (PI) staining.
For the statistical analysis the Mann–Whitney test was used.
FIGURE 4 | Proposed model for the role of EVs in the targeting of CD30-negative tumor cells with the CD30 antibody drug conjugate BV. CD30 is expressed by a
number of malignant DLBCL cells and activated immunoblasts. a) The CD30 ADC BV binds to CD30+ tumor cells, is internalized and the cytotoxic compound
monomethylauristatin E (MMAE; ∗) is selectively cleaved and activated at the dipeptide valine (Val)-citrulline (Cit) by the lysosomal peptidase cathepsin B. CD30 is
also released in b) large EVs (l-EVs) by budding from the surface and c) in small EVs (s-EVs) by plasma membrane fusion of multivesicular endosomes. d) CD30+
EVs bind BV and target different cells within the tumor microenvironment, such as CD30+ or CD30- DLBCL cells. This crossfire effect might be responsible for the
strong clinical efficacy of BV even in cases with CD30- tumor cells.
cells also release PD-L1 on EVs, which increases the extent of
immunosuppression (Chen et al., 2018). EVs are small, mobile
membrane-enclosed particles, which are released by virtually all
cell types. They are regarded as fingerprints of the donor cell and
thus carry and present many typical traits of the originating cell
to malignant or bystander cells of the microenvironment, in a
membrane-associated context. For example, chronic lymphocytic
leukemia cells can activate each other during disease progression
by transferring S100-A9 in EVs (Prieto et al., 2017).
CD30 is also transported by l-EVs and s-EVs along with its
active releasing enzyme ADAM10. Because CD30 is expressed
almost exclusively by certain tissue-associated cells and the EVs
thereof, the releasing enzyme processed most CD30 before such
EVs end up in the circulation (Hansen et al., 2016). This explains
how blood contains predominantly the proteolytically processed
soluble product sCD30. Our model argues that CD30 is only
transiently expressed on EVs and the highest concentration and
functionality is restricted to the vicinity of the donor cell. Because
(i) CD30 antibodies are poorly internalized in many CD30+ cell
lines (Matthey et al., 2004), (ii) EVs together with CD30 antibody
show a good uptake in confocal microscopy and imaging flow
cytometry, and (iii) CD30 EVs contribute to the toxicity of BV
even in the CD30+ target cell P30-OH/KUBO (Supplementary
Figure 2), we speculate that BV-loaded EVs play a major role
in the therapeutic functionality of BV. However, animal models
might be helpful to further substantiate our findings.
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At the moment it is still not clear why CD30 does not
accumulate in large quantities at the target cell surface, whereas
EVs do. We know from earlier immunoelectron microscopic
studies that many EVs from L540 cells do not carry CD30
(Hansen et al., 2014). In particular, very small EVs more often lack
CD30 compared to larger ones. This is also a reason not to focus
on small EVs alone in this study and also include larger vesicles
from the 10,000 × g fraction. One might speculate that a certain
EV type preferentially participates in EV-dependent targeting of
DLBCL cells. Based on their size, EVs are arbitrarily categorized
into multivesicular body-derived small (30–100 nm) or large
exosomes (80–120 nm), plasma membrane-derived microvesicles
(100–1,000 nm) and apoptotic bodies (>1,000 nm), the latter
derived from dying cells. Except for apoptotic bodies, healthy
cells constitutively and especially upon stimulation release a
mixture of different vesicle types. Notably, EVs can be isolated
by different methods and the selected procedure might influence
the enrichment of individual types of vesicles. To avoid this
risk, we pooled the EV fractions. Another interesting aspect
is the fact that EVs show a strong expression of ADAM10, a
major sheddase of CD30. The sheddase is not only active on
cells but also cleaving CD30 on EVs (Hansen et al., 2016).
A slow depletion of CD30 might be the reason that CD30+ EVs
are barely found in the peripheral blood of cHL patients. The
limitation of CD30+ EVs to the tumor microenvironment is at
least partially explaining the robust clinical efficacy and the mild
systemic off-target effects of BV.
CONCLUSION
The detailed mode of action of the CD30 antibody-drug
conjugate BV in DLBCL is not well understood in all aspects
since the clinical outcome seems to be partially independent of
the CD30 expression on the tumor cells. Since CD30+ bystander
cells are enriched in the tumor tissue in many cases of DLBCL,
CD30 might however be released with EVs. We thus propose
a model that even in the absence of CD30 on the tumor cells
to be targeted, EVs can transport the targeting protein from
cells of the tumor microenvironment to tumor cells (Figure 4).
This in vitro model explains the clinical efficacy of BV also in
cases when tumor cells lack the targeting antigen. Because CD30
is not only overexpressed on certain lymphomas but also on
certain activated bystander cells in other diseases, BV might be
a promising therapeutic option to treat other malignancies or
immune diseases.
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